Publicaciones en las que colabora con Maria del Carmen Ochoa Nieto (18)

2023

  1. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

2015

  1. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2013

  1. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein

    Cancer Research, Vol. 73, Núm. 1, pp. 139-149

  2. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

  3. Interleukin-15 in gene therapy of cancer

    Current Gene Therapy, Vol. 13, Núm. 1, pp. 15-30

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

2011

  1. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  2. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

  3. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

2010

  1. Interferon producing killer dendritic cells (IKDC): A matter of controversy

    Inmunologia, Vol. 29, Núm. 1, pp. 50-55

  2. Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo

    Gene Therapy

  3. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

2008

  1. Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties

    Inmunologia, Vol. 27, Núm. 4, pp. 205-211

  2. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906